Figure 4

Progression free survival by treatment arm and MAP-tau status in TAX 307S whole tissue sections. (a) Survival analysis for TAC vs FAC-treated patients (not stratified by MAP-tau) in TAX 307S indicated no treatment difference for TTP and confirmed original TAX 307 clinical trial results (n = 484). (B) Median progression free survival for patients classified as high MAP-tau expressors (n = 35) was 33.0 v 23.4 months compared with low expressors (n = 73) with mean TTP of 31.2 months (log-rank, P = 0.010). (c) Median progression-free survival for MAP-tau expression stratified by TAC or FAC treatment showing strong prognostic value for MAP-tau. Progression-free survival of 35.5 and 31.7 months for high MAP-tau expression, regardless of treatment arm (TAC or FAC/Tau high, n = 20, n = 15, respectively) compared with 20.6 and 25.0 months for low MAP-tau expression (TAC or FAC/Tau low, n = 34, n = 39), respectively indicating strong prognostic value for MAP-tau (log-rank, P = 0.006). (d) Kaplan Meier survival analysis for MAP-tau expression stratified by estrogen receptor (ER) status showing no association between ER status and MAP-tau expression (P = 0.0615).